Diagnostic challenges of hepatitis C virus infections.
In less than 10 years, tremendous progress has been made in our understanding of the biology of hepatitis C virus. Since it was defined as the causal agent of most hepatitis non-A, non-B infections in 1989, clinical laboratories now have access to powerful new techniques for the diagnosis of infection and control of therapy. Identification of the specific virus strain in the patients as well as measurement of the individual viral load and the prediction of a possible therapeutic success have become routine procedures. This effort is warranted because the treatment options are still limited, with alpha-interferon being the only approved drug. No new treatment regimens have emerged yet from the wealth of data from subtyping and quantitating.